CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS is a research journal that publishes research related to Radiology, Nuclear Medicine and Imaging. This journal is published by the Mary Ann Liebert. The P-ISSN of this journal is 10849785. Based on the Scopus data, the SCImago Journal Rank (SJR) of CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS is 0.716.
Also, check the other important details below like Publisher, ISSN, Ranking, Indexing, Impact Factor (if applicable), Publication fee (APC), Review Time, and Acceptance Rate of CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS.
According to Clarivate's JCR, the journals indexed in SCIE/SSCI have an impact factor.
The Impact Factor of CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS is 3.632.
The impact factor (IF) is a measure of the frequency with which the average article in a journal has been cited in a particular year. It is used to measure the importance or rank of a journal by calculating the times its articles are cited.
The impact factor was devised by Eugene Garfield, the founder of the Institute for Scientific Information (ISI) in Philadelphia. Impact factors began to be calculated yearly starting from 1975 for journals listed in the Journal Citation Reports (JCR). ISI was acquired by Thomson Scientific & Healthcare in 1992, and became known as Thomson ISI. In 2018, Thomson-Reuters spun off and sold ISI to Onex Corporation and Baring Private Equity Asia. They founded a new corporation, Clarivate, which is now the publisher of the JCR.
|Journal Title:||Cancer Biotherapy and Radiopharmaceuticals|
|Publisher:||Mary Ann Liebert|
|Subject:||Radiology, Nuclear Medicine and Imaging|
The CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS is indexed in:
An indexed journal means that the journal has gone through and passed a review process of certain requirements done by a journal indexer.
The Web of Science Core Collection includes the Science Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI), Arts & Humanities Citation Index (AHCI), and Emerging Sources Citation Index (ESCI).
The impact factor (IF) is a measure of the frequency with which the average article in a journal has been cited in a particular year. It is used to measure the importance or rank of a journal by calculating the times it's articles are cited.
Note: Every year, The Clarivate releases the Journal Citation Report (JCR). The JCR provides information about academic journals including impact factor. The latest JCR was released in june, 2022. The JCR 2023 will be released on 30th June 2023.
Each subject category of journals is divided into four quartiles: Q1, Q2, Q3, Q4. Q1 is occupied by the top 25% of journals in the list; Q2 is occupied by journals in the 25 to 50% group; Q3 is occupied by journals in the 50 to 75% group and Q4 is occupied by journals in the 75 to 100% group.
Visit to the official website of the journal/ conference to check the details about call for papers.
This journal covers the fields/ categories related to Radiology, Nuclear Medicine and Imaging. If your research field is related to Radiology, Nuclear Medicine and Imaging, then visit the official website of CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS and send your manuscript.
Journals usually ask reviewers to provide their reviews within 3-4 weeks. However, few journals have a mechanism to enforce the deadline, which is why it can be hard to predict how long the peer review process will take.
The review time also depends upon the quality of a research paper.